Heart and Electrolytes

  • F. Schiraldi
  • P. Ferraro
  • B. Maglione
Conference paper


Critically ill patients often have electrical instability of the heart, either due to intrinsic cardiac diseases or to electrolyte and acid-base imbalance. In addition, they are submitted to aggressive drug therapies (inotropic drugs, amines, antiarrhythmics, etc.), which may badly influence myocardial excitability, provoking eventually a proarrhythmic effect [1–3]. In order to improve the therapeutic strategies in such patients, it could be perhaps useful to recall some basic principles about the electrolyte mediated physiologic properties of the heart. Moreover, this reevaluation will hopefully offer a deeper insight on the real cellular mechanisms underlying the antiarrhythmic action of different drugs [4].


Antiarrhythmic Drug Proarrhythmic Effect Transmembrane Voltage Digitalis Toxicity Early Afterdepolarizations 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Task Force of the Working Group on Arrhythmias of the European Society of Cardiology (1991) The Sicilian Gambit. Circulation 84: 1831–1851CrossRefGoogle Scholar
  2. 2.
    Morganroth J (1992) Proarrhythmic effects of antiarrhythmic drugs: evolving concepts. Am Heart J 128: 575–586Google Scholar
  3. 3.
    Atlee JL (1997) Perioperative cardiac dysrhythmias. Anesthesiology 86: 1397–1424PubMedCrossRefGoogle Scholar
  4. 4.
    Kerin N, Somberg J (1994) Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J 128: 575–586PubMedCrossRefGoogle Scholar
  5. 5.
    Tsuji H, Venditti FJ et al (1994) The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 74: 232–235PubMedCrossRefGoogle Scholar
  6. 6.
    Gettes L (1994) Electrolyte abnormalities as triggers for lethal ventricular arrhythmias. In: Akhtar (ed) Sudden cardiac death. Williams and Wilkins, Philadelphia, pp 327–340Google Scholar
  7. 7.
    Curran ME, Splawsky I et al (1995) Amolecular basis for cardiac arrhytmias: HERG mutations cause long QT syndrome. Cell 80: 795–803Google Scholar
  8. 8.
    Oreto G (1997) I disordini del ritmo cardiaco. Centro Scientifico Editore, TorinoGoogle Scholar
  9. 9.
    Singh BN (1993) Controlling cardiac arrhythmias by lengthening repolarization: emerging perspectives. Am J Card 72;16:1F-124 FGoogle Scholar
  10. 10.
    Sanguinetti MC, Jiang C et al (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ik potassium channel. Cell 81: 299–307Google Scholar
  11. 11.
    Hondeghem LM (1987) Antiarrhythmic agents. Modulated receptors applications. Circulation 75: 514–520PubMedCrossRefGoogle Scholar
  12. 12.
    Roden DM (1994) Risks and benefits of antiarrhythmic therapy. N Engl J Med 331: 785–791PubMedCrossRefGoogle Scholar
  13. 13.
    Seller RH (1971) The role of magnesium in digitalis toxicity. Am Heart J 82: 551–556PubMedCrossRefGoogle Scholar
  14. 14.
    Atlee JL (1998) New concepts of antiarrhythmic strategies. In: Gullo A (ed) APICE Proceedings. Springer Verlag, pp 291–297Google Scholar
  15. 15.
    Kowey PR, Marinchak RA et al (1997) Intravenous amiodarone. J Am Coll Cardiol 29: 1190–1198PubMedCrossRefGoogle Scholar
  16. 16.
    Daoud EG, Strickberger SA et al (1997) Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgeryGoogle Scholar
  17. 17.
    Tzivoni D, Banai S et al (1988) Treatment of torsade de pointes with magnesium sulfate. Circulation 77: 392–397PubMedCrossRefGoogle Scholar
  18. 18.
    Schiraldi F (1993) Acqua, elettroliti, equilibrio acido-base: l’essenziale. Ed. Idelson, NapoliGoogle Scholar
  19. 19.
    The CAST Investigators (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–412CrossRefGoogle Scholar
  20. 20.
    Mason JW (1987) Amiodarone. N Engl J Med 316: 455–458CrossRefGoogle Scholar
  21. 21.
    Funck-Brentano C, Kroemer HK et al (1990) Propafenone. N Engl J Med 322: 518–525CrossRefGoogle Scholar
  22. 22.
    The Sicilian Gambit (1994) Antiarrhythmic therapy: a pathophysiologic approach. Futura, Armonk, pp 3–337Google Scholar
  23. 23.
    Steinbach KK, Merl O et al (1994) Hemodynamics during ventricular tachyanhytmias. Am Heart J 127: 1102–1106PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • F. Schiraldi
  • P. Ferraro
  • B. Maglione

There are no affiliations available

Personalised recommendations